Table 1.
Study population.
| SARS-CoV-2, n = 206 | Control, n = 206 | Missing values, SARS-CoV-2/control | |
|---|---|---|---|
| Demographics/biometrics | |||
| Age (years) | 47.0 ± 15.2 | 47.0 ± 15.0 | 0/0 |
| 18–39 (no. (%)) | 69 (33.5) | 63 (30.6) | 0/0 |
| 40 (no. (%)) | 93 (45.1) | 97 (47.1) | 0/0 |
| 60–79 (no. (%)) | 43 (20.9) | 46 (22.3) | 0/0 |
| ≥80 (no. (%)) | 1 (0.01) | 0 (0) | 0/0 |
|
| |||
| Gender | |||
| Male (no. (%)) | 86 (41.8) | 86 (41.8) | 0/0 |
| Female (no. (%)) | 120 (58.2) | 120 (58.2) | 0/0 |
|
| |||
| Body mass index (kg/m2) | 25.3 ± 4.0 | 24.8 ± 4.3 | 4/0 |
|
| |||
| Cardiovascular risk factors | |||
| Diabetes mellitus (no. (%)) | 1 (0.5) | 1 (0.5) | 0/0 |
| Arterial hypertension (no. (%)) | 27 (13.1) | 27 (13.1) | 0/0 |
| Hypercholesterolemia (no. (%)) | 24 (11.6) | 15 (7.3) | 2/0 |
| Smoking (no. (%)) | 79 (36.9) | 79 (36.9) | 0/0 |
| Family history of coronary artery disease (no. (%)) | 37 (18.9) | 36 (17.5) | 3/2 |
|
| |||
| Clinical history | |||
| Chronic obstructive pulmonary disease (no. (%)) | 3 (1.5) | 2 (1.0) | 10/6 |
| Interstitial lung disease (no. (%)) | 0 (0.0) | 0 (0.0) | 9/7 |
| Pulmonary embolism (no. (%)) | 1 (0.5) | 1 (0.5) | 8/7 |
| Deep vein thrombosis (no. (%)) | 2 (1.0) | 4 (1.9) | 9/7 |
| Asthma (no. (%)) | 18 (8.9) | 8 (3.9) | 22/12 |
| Myocardial infarction (no. (%)) | 3 (1.5) | 3 (1.5) | 0/0 |
| Transient ischemic attack/stroke (no. (%)) | 2 (1.0) | 2 (1.0) | 0/0 |
| Coronary artery disease (no. (%)) | 4 (1.9) | 4 (1.9) | 0/0 |
| Peripheral artery disease (no. (%)) | 1 (0.5) | 1 (0.5) | 1/0 |
Data are given as absolute value (percentage)/mean ± standard deviation.